Checkpoint blockade therapies with monoclonal antibodies targeting inhibitory receptors such as CTLA-4 and PD-1 on CD8+ T lymphocytes have been developed to override cell intrinsic mechanisms that limit overstimulation of T cells and have dramatically improved both antitumor T cell function and clinical responses in melanoma patients. This evidence concerns the gene CD8A and melanoma.